Department of Translational Medical Sciences, University of Naples "Federico II", 80138 Naples, Italy.
Farcoderm S.r.l., 27028 San Martino Siccomario, Italy.
Int J Mol Sci. 2023 Jul 27;24(15):12063. doi: 10.3390/ijms241512063.
Estrogen deficiency is a major cause of loss of postmenopausal bone mineral density (BMD). This study aimed to evaluate the effects of equol and resveratrol on bone turnover biomarkers in postmenopausal women. Sixty healthy postmenopausal women were randomly assigned to receive 200 mg fermented soy containing 10 mg equol and 25 mg resveratrol or a placebo for 12 months. Whole-body BMD and bone turnover biomarkers, such as deoxypyridinoline (DPD), tartrate-resistant acid phosphatase 5b (TRACP-5b), osteocalcin, and bone-specific alkaline phosphatase (BAP), were measured at baseline and after 12 months of treatment. At the end of treatment, DPD, osteocalcin, and BAP significantly improved in the active group ( < 0.0001 for all) compared to the placebo group. Conversely, TRACP-5b levels were unaffected by supplementation ( = 0.051). Statistically significant changes in the concentrations of DPD ( < 0.0001), osteocalcin ( = 0.0001), and BAP ( < 0.0001) compared to baseline were also identified. Overall, the intervention significantly increased BMD measured in the whole body ( = 0.0220) compared with the placebo. These data indicate that the combination of equol and resveratrol may positively modulate bone turnover biomarkers and BMD, representing a potential approach to prevent age-related bone loss in postmenopausal women.
雌激素缺乏是绝经后骨密度（BMD）丧失的主要原因。本研究旨在评估依普黄酮和白藜芦醇对绝经后妇女骨转换生物标志物的影响。60 名健康绝经后妇女被随机分为接受 200 毫克含有 10 毫克依普黄酮和 25 毫克白藜芦醇的发酵大豆或安慰剂治疗 12 个月。在基线和治疗 12 个月后测量全身 BMD 和骨转换生物标志物，如脱氧吡啶啉（DPD）、抗酒石酸酸性磷酸酶 5b（TRACP-5b）、骨钙素和骨特异性碱性磷酸酶（BAP）。治疗结束时，与安慰剂组相比，活性组的 DPD、骨钙素和 BAP 显著改善（所有 P<0.0001）。相反，TRACP-5b 水平不受补充剂的影响（P=0.051）。与基线相比，DPD（P<0.0001）、骨钙素（P=0.0001）和 BAP（P<0.0001）的浓度也发生了统计学上显著的变化。与安慰剂相比，干预措施使全身 BMD 显著增加（P=0.0220）。这些数据表明，依普黄酮和白藜芦醇的联合使用可能会积极调节骨转换生物标志物和 BMD，代表了一种预防绝经后妇女与年龄相关的骨丢失的潜在方法。
